[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse INSR

Summary
SymbolINSR
Nameinsulin receptor
Aliases CD220; HHF5; IR; CD antigen CD220
Chromosomal Location19p13.3-p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Single-pass type I membrane protein.
Domain PF00757 Furin-like cysteine rich region
PF07714 Protein tyrosine kinase
PF01030 Receptor L domain
Function

Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosine residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT/PKB is responsible for: anti-apoptotic effect of insulin by inducing phosphorylation of BAD; regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K-AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII binding. When present in a hybrid receptor with IGF1R, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.

> Gene Ontology
 
Biological Process GO:0000187 activation of MAPK activity
GO:0000271 polysaccharide biosynthetic process
GO:0003007 heart morphogenesis
GO:0005976 polysaccharide metabolic process
GO:0005977 glycogen metabolic process
GO:0005978 glycogen biosynthetic process
GO:0005979 regulation of glycogen biosynthetic process
GO:0005996 monosaccharide metabolic process
GO:0006006 glucose metabolic process
GO:0006073 cellular glucan metabolic process
GO:0006090 pyruvate metabolic process
GO:0006091 generation of precursor metabolites and energy
GO:0006096 glycolytic process
GO:0006109 regulation of carbohydrate metabolic process
GO:0006110 regulation of glycolytic process
GO:0006112 energy reserve metabolic process
GO:0006140 regulation of nucleotide metabolic process
GO:0006165 nucleoside diphosphate phosphorylation
GO:0006260 DNA replication
GO:0006275 regulation of DNA replication
GO:0006732 coenzyme metabolic process
GO:0006733 oxidoreduction coenzyme metabolic process
GO:0006757 ATP generation from ADP
GO:0006809 nitric oxide biosynthetic process
GO:0007067 mitotic nuclear division
GO:0007088 regulation of mitotic nuclear division
GO:0007346 regulation of mitotic cell cycle
GO:0007507 heart development
GO:0007530 sex determination
GO:0007548 sex differentiation
GO:0008286 insulin receptor signaling pathway
GO:0008406 gonad development
GO:0008544 epidermis development
GO:0008584 male gonad development
GO:0008585 female gonad development
GO:0008643 carbohydrate transport
GO:0008645 hexose transport
GO:0009116 nucleoside metabolic process
GO:0009118 regulation of nucleoside metabolic process
GO:0009119 ribonucleoside metabolic process
GO:0009123 nucleoside monophosphate metabolic process
GO:0009126 purine nucleoside monophosphate metabolic process
GO:0009132 nucleoside diphosphate metabolic process
GO:0009135 purine nucleoside diphosphate metabolic process
GO:0009141 nucleoside triphosphate metabolic process
GO:0009144 purine nucleoside triphosphate metabolic process
GO:0009150 purine ribonucleotide metabolic process
GO:0009161 ribonucleoside monophosphate metabolic process
GO:0009167 purine ribonucleoside monophosphate metabolic process
GO:0009179 purine ribonucleoside diphosphate metabolic process
GO:0009185 ribonucleoside diphosphate metabolic process
GO:0009199 ribonucleoside triphosphate metabolic process
GO:0009205 purine ribonucleoside triphosphate metabolic process
GO:0009250 glucan biosynthetic process
GO:0009894 regulation of catabolic process
GO:0009896 positive regulation of catabolic process
GO:0010675 regulation of cellular carbohydrate metabolic process
GO:0010676 positive regulation of cellular carbohydrate metabolic process
GO:0010827 regulation of glucose transport
GO:0010828 positive regulation of glucose transport
GO:0010906 regulation of glucose metabolic process
GO:0010907 positive regulation of glucose metabolic process
GO:0010962 regulation of glucan biosynthetic process
GO:0015749 monosaccharide transport
GO:0015758 glucose transport
GO:0015980 energy derivation by oxidation of organic compounds
GO:0016051 carbohydrate biosynthetic process
GO:0016052 carbohydrate catabolic process
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0019048 modulation by virus of host morphology or physiology
GO:0019087 transformation of host cell by virus
GO:0019318 hexose metabolic process
GO:0019362 pyridine nucleotide metabolic process
GO:0030238 male sex determination
GO:0030325 adrenal gland development
GO:0030335 positive regulation of cell migration
GO:0031016 pancreas development
GO:0031017 exocrine pancreas development
GO:0031329 regulation of cellular catabolic process
GO:0031331 positive regulation of cellular catabolic process
GO:0032147 activation of protein kinase activity
GO:0032148 activation of protein kinase B activity
GO:0032868 response to insulin
GO:0032869 cellular response to insulin stimulus
GO:0032881 regulation of polysaccharide metabolic process
GO:0032885 regulation of polysaccharide biosynthetic process
GO:0033500 carbohydrate homeostasis
GO:0033674 positive regulation of kinase activity
GO:0033692 cellular polysaccharide biosynthetic process
GO:0034637 cellular carbohydrate biosynthetic process
GO:0035270 endocrine system development
GO:0035272 exocrine system development
GO:0035821 modification of morphology or physiology of other organism
GO:0038083 peptidyl-tyrosine autophosphorylation
GO:0040017 positive regulation of locomotion
GO:0042278 purine nucleoside metabolic process
GO:0042593 glucose homeostasis
GO:0043255 regulation of carbohydrate biosynthetic process
GO:0043405 regulation of MAP kinase activity
GO:0043406 positive regulation of MAP kinase activity
GO:0043410 positive regulation of MAPK cascade
GO:0043434 response to peptide hormone
GO:0043467 regulation of generation of precursor metabolites and energy
GO:0043470 regulation of carbohydrate catabolic process
GO:0043491 protein kinase B signaling
GO:0044003 modification by symbiont of host morphology or physiology
GO:0044042 glucan metabolic process
GO:0044262 cellular carbohydrate metabolic process
GO:0044264 cellular polysaccharide metabolic process
GO:0044723 single-organism carbohydrate metabolic process
GO:0044724 single-organism carbohydrate catabolic process
GO:0045137 development of primary sexual characteristics
GO:0045428 regulation of nitric oxide biosynthetic process
GO:0045429 positive regulation of nitric oxide biosynthetic process
GO:0045725 positive regulation of glycogen biosynthetic process
GO:0045730 respiratory burst
GO:0045740 positive regulation of DNA replication
GO:0045787 positive regulation of cell cycle
GO:0045821 positive regulation of glycolytic process
GO:0045840 positive regulation of mitotic nuclear division
GO:0045860 positive regulation of protein kinase activity
GO:0045913 positive regulation of carbohydrate metabolic process
GO:0045927 positive regulation of growth
GO:0045931 positive regulation of mitotic cell cycle
GO:0045979 positive regulation of nucleoside metabolic process
GO:0045981 positive regulation of nucleotide metabolic process
GO:0045995 regulation of embryonic development
GO:0046031 ADP metabolic process
GO:0046034 ATP metabolic process
GO:0046128 purine ribonucleoside metabolic process
GO:0046209 nitric oxide metabolic process
GO:0046323 glucose import
GO:0046324 regulation of glucose import
GO:0046326 positive regulation of glucose import
GO:0046496 nicotinamide nucleotide metabolic process
GO:0046545 development of primary female sexual characteristics
GO:0046546 development of primary male sexual characteristics
GO:0046660 female sex differentiation
GO:0046661 male sex differentiation
GO:0046777 protein autophosphorylation
GO:0046939 nucleotide phosphorylation
GO:0048608 reproductive structure development
GO:0048638 regulation of developmental growth
GO:0048639 positive regulation of developmental growth
GO:0048732 gland development
GO:0051052 regulation of DNA metabolic process
GO:0051054 positive regulation of DNA metabolic process
GO:0051186 cofactor metabolic process
GO:0051193 regulation of cofactor metabolic process
GO:0051194 positive regulation of cofactor metabolic process
GO:0051196 regulation of coenzyme metabolic process
GO:0051197 positive regulation of coenzyme metabolic process
GO:0051259 protein oligomerization
GO:0051262 protein tetramerization
GO:0051272 positive regulation of cellular component movement
GO:0051290 protein heterotetramerization
GO:0051291 protein heterooligomerization
GO:0051321 meiotic cell cycle
GO:0051445 regulation of meiotic cell cycle
GO:0051446 positive regulation of meiotic cell cycle
GO:0051701 interaction with host
GO:0051783 regulation of nuclear division
GO:0051785 positive regulation of nuclear division
GO:0051817 modification of morphology or physiology of other organism involved in symbiotic interaction
GO:0051896 regulation of protein kinase B signaling
GO:0051897 positive regulation of protein kinase B signaling
GO:0055123 digestive system development
GO:0060263 regulation of respiratory burst
GO:0060267 positive regulation of respiratory burst
GO:0061458 reproductive system development
GO:0070873 regulation of glycogen metabolic process
GO:0070875 positive regulation of glycogen metabolic process
GO:0071375 cellular response to peptide hormone stimulus
GO:0071417 cellular response to organonitrogen compound
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
GO:0072524 pyridine-containing compound metabolic process
GO:0072593 reactive oxygen species metabolic process
GO:0090068 positive regulation of cell cycle process
GO:1900542 regulation of purine nucleotide metabolic process
GO:1900544 positive regulation of purine nucleotide metabolic process
GO:1901652 response to peptide
GO:1901653 cellular response to peptide
GO:1901657 glycosyl compound metabolic process
GO:1903409 reactive oxygen species biosynthetic process
GO:1903426 regulation of reactive oxygen species biosynthetic process
GO:1903428 positive regulation of reactive oxygen species biosynthetic process
GO:1903578 regulation of ATP metabolic process
GO:1903580 positive regulation of ATP metabolic process
GO:1904407 positive regulation of nitric oxide metabolic process
GO:2000147 positive regulation of cell motility
GO:2000194 regulation of female gonad development
GO:2000241 regulation of reproductive process
GO:2000243 positive regulation of reproductive process
GO:2000377 regulation of reactive oxygen species metabolic process
GO:2000379 positive regulation of reactive oxygen species metabolic process
GO:2001057 reactive nitrogen species metabolic process
Molecular Function GO:0004713 protein tyrosine kinase activity
GO:0004714 transmembrane receptor protein tyrosine kinase activity
GO:0004716 receptor signaling protein tyrosine kinase activity
GO:0005009 insulin-activated receptor activity
GO:0005057 receptor signaling protein activity
GO:0005159 insulin-like growth factor receptor binding
GO:0005520 insulin-like growth factor binding
GO:0005525 GTP binding
GO:0017046 peptide hormone binding
GO:0019001 guanyl nucleotide binding
GO:0019199 transmembrane receptor protein kinase activity
GO:0019838 growth factor binding
GO:0031994 insulin-like growth factor I binding
GO:0031995 insulin-like growth factor II binding
GO:0032561 guanyl ribonucleotide binding
GO:0033218 amide binding
GO:0042277 peptide binding
GO:0042562 hormone binding
GO:0043548 phosphatidylinositol 3-kinase binding
GO:0043559 insulin binding
GO:0043560 insulin receptor substrate binding
GO:0051425 PTB domain binding
Cellular Component GO:0005899 insulin receptor complex
GO:0005901 caveola
GO:0010008 endosome membrane
GO:0043235 receptor complex
GO:0044440 endosomal part
GO:0044853 plasma membrane raft
GO:0045121 membrane raft
GO:0061695 transferase complex, transferring phosphorus-containing groups
GO:0098589 membrane region
GO:0098802 plasma membrane receptor complex
GO:0098857 membrane microdomain
GO:1902911 protein kinase complex
> KEGG and Reactome Pathway
 
KEGG hsa04014 Ras signaling pathway
hsa04015 Rap1 signaling pathway
hsa04022 cGMP-PKG signaling pathway
hsa04066 HIF-1 signaling pathway
hsa04068 FoxO signaling pathway
hsa04150 mTOR signaling pathway
hsa04151 PI3K-Akt signaling pathway
hsa04152 AMPK signaling pathway
hsa04520 Adherens junction
hsa04910 Insulin signaling pathway
hsa04913 Ovarian steroidogenesis
hsa04960 Aldosterone-regulated sodium reabsorption
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-186763: Downstream signal transduction
R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR)
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-180292: GAB1 signalosome
R-HSA-74713: IRS activation
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-77387: Insulin receptor recycling
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-199418: Negative regulation of the PI3K/AKT network
R-HSA-198203: PI3K/AKT activation
R-HSA-6811558: PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
R-HSA-1257604: PIP3 activates AKT signaling
R-HSA-2730905: Role of LAT2/NTAL/LAB on calcium mobilization
R-HSA-162582: Signal Transduction
R-HSA-74749: Signal attenuation
R-HSA-177929: Signaling by EGFR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-983705: Signaling by the B Cell Receptor (BCR)
R-HSA-166520: Signalling by NGF
Summary
SymbolINSR
Nameinsulin receptor
Aliases CD220; HHF5; IR; CD antigen CD220
Chromosomal Location19p13.3-p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between INSR and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolINSR
Nameinsulin receptor
Aliases CD220; HHF5; IR; CD antigen CD220
Chromosomal Location19p13.3-p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of INSR in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
24476824shRNAmelanomaB16Secondary screen Total # shRNA with >= 4-fold: 2 Resistant to T-cell proliferation
Summary
SymbolINSR
Nameinsulin receptor
Aliases CD220; HHF5; IR; CD antigen CD220
Chromosomal Location19p13.3-p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of INSR in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1090.687
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.2630.8
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3890.563
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.5130.103
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2450.92
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.8520.785
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3260.424
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.8180.566
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2280.887
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.1630.432
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.7970.401
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0890.286
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of INSR in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.15.91.21
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1031033.3-23.30.423
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.75.5-1.81
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.76.8-3.11
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.317.6-3.31
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131123.118.24.91
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.218.83.41
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592022.2-2.21
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 472514.310.71
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolINSR
Nameinsulin receptor
Aliases CD220; HHF5; IR; CD antigen CD220
Chromosomal Location19p13.3-p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of INSR. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolINSR
Nameinsulin receptor
Aliases CD220; HHF5; IR; CD antigen CD220
Chromosomal Location19p13.3-p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of INSR. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by INSR.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolINSR
Nameinsulin receptor
Aliases CD220; HHF5; IR; CD antigen CD220
Chromosomal Location19p13.3-p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of INSR. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolINSR
Nameinsulin receptor
Aliases CD220; HHF5; IR; CD antigen CD220
Chromosomal Location19p13.3-p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of INSR expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolINSR
Nameinsulin receptor
Aliases CD220; HHF5; IR; CD antigen CD220
Chromosomal Location19p13.3-p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between INSR and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolINSR
Nameinsulin receptor
Aliases CD220; HHF5; IR; CD antigen CD220
Chromosomal Location19p13.3-p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting INSR collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting INSR.
ID Name Drug Type Targets #Targets
DB00030Insulin HumanBiotechCPE, CTSD, IDE, IGF1R, IGFBP7, INSR, LRP2, NOV, PCSK1, PCSK2, RB1, ......12
DB00046Insulin LisproBiotechIGF1R, INSR2
DB00047Insulin GlargineBiotechIGF1R, INSR2
DB00071Insulin PorkBiotechCPE, CTSD, HLA-DQA2, HLA-DQB1, IDE, IGF1R, IGFBP7, INSR, LRP2, NOV ......14
DB01277MecaserminBiotechIGF1R, IGF2R, IGFBP3, INSR4
DB01306Insulin AspartBiotechINSR1
DB01307Insulin DetemirBiotechINSR1
DB01309Insulin GlulisineBiotechINSR1
DB03909Adenosine-5'-[Beta, Gamma-Methylene]TriphosphateSmall MoleculeATP2A1, INSR, KIF1A, PDXK, PGK15
DB05115NN344Small MoleculeINSR1
DB05120AT1391Small MoleculeINSR1
DB08513[4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACIDSmall MoleculeINSR, IRS1, MAPK13
DB09129Chromic chlorideSmall MoleculeINSR1
DB09564Insulin DegludecBiotechINSR1
DB12267BrigatinibSmall MoleculeABL1, ALK, EGFR, ERBB2, ERBB4, FLT3, IGF1R, INSR, MET9